Immunogen (FRA:IMU) COGS-to-Revenue : 0.02 (As of Sep. 2023)

View and export this data going back to . Start your Free Trial

What is Immunogen COGS-to-Revenue?

Immunogen's Cost of Goods Sold for the three months ended in Sep. 2023 was €2.0 Mil. Its Revenue for the three months ended in Sep. 2023 was €106.3 Mil.

Immunogen's COGS to Revenue for the three months ended in Sep. 2023 was 0.02.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Immunogen's Gross Margin % for the three months ended in Sep. 2023 was 98.10%.

Immunogen COGS-to-Revenue Historical Data

The historical data trend for Immunogen's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunogen COGS-to-Revenue Chart

Immunogen Annual Data

Trend

Jun13

Jun14

Jun15

Jun16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

COGS-to-Revenue

Get a 7-Day Free Trial

Immunogen Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	0.01	0.01	0.02

Immunogen COGS-to-Revenue Calculation

Immunogen's COGS to Revenue for the fiscal year that ended in Dec. 2022 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.166	/	102.69
	=	0.00

Immunogen's COGS to Revenue for the quarter that ended in Sep. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	2.019	/	106.279
	=	0.02

Immunogen (FRA:IMU) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Immunogen's Gross Margin % for the three months ended in Sep. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	2.019 / 106.279
	=	98.10 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Immunogen COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Immunogen's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunogen (FRA:IMU) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunogen Inc (FRA:IMU) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

IMGN:USA IMGN:Mexico

Address

830 Winter Street, Waltham, MA, USA, 02451

Website

https://www.immunogen.com

Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent.

Immunogen (FRA:IMU) Headlines

No Headlines